[go: up one dir, main page]

RS50023B - Farmaceutski sastav koji sadrži inhibitore protonske pumpe - Google Patents

Farmaceutski sastav koji sadrži inhibitore protonske pumpe

Info

Publication number
RS50023B
RS50023B YUP-504/01A YUP50401A RS50023B RS 50023 B RS50023 B RS 50023B YU P50401 A YUP50401 A YU P50401A RS 50023 B RS50023 B RS 50023B
Authority
RS
Serbia
Prior art keywords
pharmaceutical composition
composition containing
proton pump
pump inhibitors
containing proton
Prior art date
Application number
YUP-504/01A
Other languages
English (en)
Inventor
Keith Freehauf
Original Assignee
Merck & Co. Inc.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co. Inc., filed Critical Merck & Co. Inc.,
Publication of YU50401A publication Critical patent/YU50401A/sh
Publication of RS50023B publication Critical patent/RS50023B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Farmaceutska formulacija za oralnu primenu, naznačena time, što uključuje. (a) 1% do 60% m/m omeprazola, (b) 0.1 % do 2% m/m od dva do četiri sredstva za bazifikaciju, (c) 1 % do 3% m/m sredstva za zgušnjavanje, i (d) hidrofobni uljasti tečni nosač koji uključuje (i) biljno ulje i (ii) trigliceride masnih kiselina sa srednjom dužinom lanca sa od 8-12 ugljenikovih atoma ili propilen-glikolne diestre masnih kiselina sa srednjom dužinom lanca - od 8-12 ug1jenikovih atoma. Prijava ima još 10 zahteva.
YUP-504/01A 1999-02-23 2000-02-18 Farmaceutski sastav koji sadrži inhibitore protonske pumpe RS50023B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12125399P 1999-02-23 1999-02-23

Publications (2)

Publication Number Publication Date
YU50401A YU50401A (sh) 2004-05-12
RS50023B true RS50023B (sr) 2008-09-29

Family

ID=22395498

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-504/01A RS50023B (sr) 1999-02-23 2000-02-18 Farmaceutski sastav koji sadrži inhibitore protonske pumpe

Country Status (31)

Country Link
US (1) US6316481B1 (sr)
EP (1) EP1156806B1 (sr)
JP (1) JP2002537337A (sr)
KR (1) KR100701448B1 (sr)
CN (1) CN1227009C (sr)
AR (1) AR029615A1 (sr)
AT (1) ATE263562T1 (sr)
AU (1) AU771061B2 (sr)
BG (1) BG65291B1 (sr)
BR (1) BR0008403A (sr)
CA (1) CA2362932C (sr)
CO (1) CO5140102A1 (sr)
CZ (1) CZ301647B6 (sr)
DE (1) DE60009675T2 (sr)
DK (1) DK1156806T3 (sr)
EA (1) EA004683B1 (sr)
ES (1) ES2216870T3 (sr)
HK (1) HK1041650A1 (sr)
HR (1) HRP20010615B1 (sr)
HU (1) HU228181B1 (sr)
IL (1) IL144131A0 (sr)
ME (1) ME00864B (sr)
NO (1) NO328863B1 (sr)
NZ (1) NZ512771A (sr)
PL (1) PL195783B1 (sr)
PT (1) PT1156806E (sr)
RS (1) RS50023B (sr)
SK (1) SK286371B6 (sr)
TW (1) TW587936B (sr)
WO (1) WO2000050038A1 (sr)
ZA (1) ZA200106104B (sr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6852739B1 (en) 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
AU6746501A (en) 2000-05-30 2001-12-11 Merial Ltd Methods for prevention of ulcers and improving physiological performance
EP1341523B1 (en) 2000-12-07 2013-01-23 Nycomed GmbH Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient
DE10061135C1 (de) * 2000-12-07 2002-11-07 Byk Gulden Lomberg Chem Fab Pharmazeutische Zubereitung in Form einer Paste enthaltend einen säurelabilen Wirkstoff
AU2002231654A1 (en) 2000-12-07 2002-06-18 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Pharmaceutical paste comprising an acid-labile active ingredient
WO2004012659A2 (en) 2002-08-01 2004-02-12 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
GB2394895A (en) * 2002-11-06 2004-05-12 Cipla Ltd Proton pump inhibitor composition in paste form
WO2005000269A1 (en) * 2003-06-26 2005-01-06 Cipla Limited Pharmaceutical formulations comprising a proton pump inhibitor
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2006026829A1 (en) * 2004-09-09 2006-03-16 Metelli Pty Ltd Stable paste composition of enteric coated acid labile active agent and use thereof
CN101500553B (zh) * 2006-07-25 2012-04-18 维克塔有限公司 联合使用小分子二羧酸的衍生物与ppi用于抑制胃酸分泌的组合物和方法
CN101610754A (zh) * 2007-02-16 2009-12-23 Aska制药株式会社 含有微粒油性混悬液的药物组合物
WO2011011351A2 (en) * 2009-07-20 2011-01-27 Vetegen, Llc A stable pharmaceutical omeprazole formulation for oral administration
US8722636B2 (en) 2011-01-31 2014-05-13 New Market Pharmaceuticals, LLC Animal treatments
WO2013165468A1 (en) 2012-05-02 2013-11-07 New Market Pharmaceuticals Pharmaceutical compositions for direct systemic introduction
US10064849B2 (en) 2012-05-02 2018-09-04 New Market Pharmaceuticals Pharmaceutical compositions for direct systemic introduction
EP3057571B1 (en) * 2013-10-18 2019-03-06 Norbrook Laboratories Limited Proton pump inhibitor paste compositions
GB2524351B (en) * 2013-10-18 2016-12-14 Norbrook Lab Ltd Proton Pump Inhibitor Paste Compositions
PT3386507T (pt) 2015-12-08 2023-09-11 Luoda Pharma Ltd Métodos e composições para tratar úlceras gástricas
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2018031935A1 (en) 2016-08-11 2018-02-15 Adamis Pharmaceuticals Corporation Drug compositions
WO2019113493A1 (en) 2017-12-08 2019-06-13 Adamis Pharmaceuticals Corporation Drug compositions
ES2723873B1 (es) * 2018-03-01 2020-05-13 Hernan Ma Carmen Batanero Medicamento combinado con omeprazol y vitamina B12
CN112972481A (zh) * 2021-03-18 2021-06-18 华农（肇庆）生物产业技术研究院有限公司 药物组合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4255432A (en) 1979-09-06 1981-03-10 Syntex (U.S.A.) Inc. 8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof
DK130287D0 (da) 1987-03-13 1987-03-13 Benzon As Alfred Oralt praeparat
SE9301489D0 (sv) 1993-04-30 1993-04-30 Ab Astra Veterinary composition
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors

Also Published As

Publication number Publication date
HRP20010615A2 (en) 2002-12-31
KR20010102297A (ko) 2001-11-15
AU3368700A (en) 2000-09-14
NZ512771A (en) 2003-02-28
AU771061B2 (en) 2004-03-11
KR100701448B1 (ko) 2007-03-30
WO2000050038A1 (en) 2000-08-31
TW587936B (en) 2004-05-21
NO20014074D0 (no) 2001-08-22
YU50401A (sh) 2004-05-12
ATE263562T1 (de) 2004-04-15
ME00864B (me) 2008-09-29
CZ20013058A3 (cs) 2001-11-14
AR029615A1 (es) 2003-07-10
EP1156806A1 (en) 2001-11-28
CZ301647B6 (cs) 2010-05-12
HUP0200325A2 (en) 2002-06-29
CA2362932A1 (en) 2000-08-31
EP1156806B1 (en) 2004-04-07
EA200100905A1 (ru) 2002-02-28
DK1156806T3 (da) 2004-08-02
NO328863B1 (no) 2010-05-31
SK12062001A3 (sk) 2001-12-03
NO20014074L (no) 2001-08-22
PL195783B1 (pl) 2007-10-31
PT1156806E (pt) 2004-07-30
BG65291B1 (bg) 2007-12-28
ZA200106104B (en) 2002-12-24
PL350729A1 (en) 2003-01-27
HRP20010615B1 (en) 2011-03-31
BR0008403A (pt) 2002-01-29
SK286371B6 (sk) 2008-08-05
CN1227009C (zh) 2005-11-16
HUP0200325A3 (en) 2003-05-28
CO5140102A1 (es) 2002-03-22
ES2216870T3 (es) 2004-11-01
HK1041650A1 (en) 2002-07-19
HU228181B1 (en) 2013-01-28
BG105754A (en) 2002-03-29
IL144131A0 (en) 2002-05-23
DE60009675T2 (de) 2005-03-24
EA004683B1 (ru) 2004-06-24
CN1341022A (zh) 2002-03-20
CA2362932C (en) 2010-11-30
US6316481B1 (en) 2001-11-13
JP2002537337A (ja) 2002-11-05
DE60009675D1 (de) 2004-05-13

Similar Documents

Publication Publication Date Title
RS50023B (sr) Farmaceutski sastav koji sadrži inhibitore protonske pumpe
TW200531696A (en) Pharmaceutical formulations of bisphosphonates
MXPA01013210A (es) Composiciones farmaceuticas y nutricionales que contienen acidos grasos esenciales y agentes que disminuyen en la homocisteina.
ES2168271T3 (es) Composiciones farmaceuticas que contienen ciclosporinas.
TR199500826A2 (tr) Multipl ünite tablet doz formu 2.
EP1226104A4 (en) PHENOXY CARBOXYLIC ACID COMPOUNDS AND COMPOSITIONS USED TO DIFFUSER ACTIVE AGENTS
PT1267832E (pt) Sistema auto-emulsionante de libertacao de farmaco
EP1100522A4 (en) ADMINISTRATION OF ACTIVE AGENTS OVER THE LUNG
DK0768867T3 (da) Doseringsform til indgivelse af lægemiddel i væskeformig formulering
ATE236627T1 (de) Pharmazeutische zubereitung enhaltend eicosapentaensäure und/oder stearidonsäure
MX9207449A (es) Inhibidores de la enzima proteolitica derivada de sacarina.
RS51764B (sr) Transdermalna farmaceutska kompozicija
MY127749A (en) Liquid formulation
ES2136252T3 (es) Tratamiento de enfermedades causadas por trastornos de la glandula sebacea mediante el uso de inhibidores de acil coa colesterol acil transferasa.
SE0000774D0 (sv) New formulation
PA8586801A1 (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
UY26303A1 (es) Composiciones farmacéuticas para administración oral y tópica
DK0710108T3 (da) Flydende, farmaceutisk præparat til oral anvendelse indeholdende 2-(4-isobutylphenyl)-propionsyre
RS49602B (sr) Farmaceutske mikrosfere valproinske kiseline za oralnu upotrebu
MA29481B1 (fr) Derives d'azolopyridine-2-one en tant qu'inhibiteurs de lipase et de phospholipase
ES2140512T3 (es) Composiciones farmaceuticas que contienen derivados de estaurosporina y un gliceridos polialquilenglicolico.
ES2044561T3 (es) Composiciones liquidas administrables por via oral a base de aceites comestibles.
ATE304374T1 (de) Topische pharmazeutische zusammensetzung zur behandlung von haut- oder zirkulatorischen krankheiten auf inflammatorischer, immun-, proliferativer oder degenerativer basis
DE69815724D1 (de) Transparente körperpflegemittel
ATE286395T1 (de) Antithrombotische mittel